Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System

计划入组 343 人 · 首次发布于 2023 年 1 月 5 日

An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis

计划入组 100 人 · 首次发布于 2017 年 3 月 23 日

An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection

计划入组 20 人 · 首次发布于 2013 年 12 月 20 日

Hygromycin B

C₂₀H₃₇N₃O₁₃

AB&B BIO-TECH-B

B R B Software Systems Inc

United States

VIGONVITA-B

Acurx Pharmaceuticals Secures New Patent for DNA Polymerase IIIC Inhibitors Targeting Antibiotic-Resistant Bacteria

Acurx Pharmaceuticals Secures Australian Patent for Novel DNA Polymerase IIIC Inhibitor Antibiotics

Acurx Pharmaceuticals Advances Ibezapolstat for C. difficile Infection